Perrigo Company Stock News

Analysts expect that Perrigo Company plc (NYSE:PRGO) will report sales of $1.09 billion for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Perrigos earnings. The highest sales estimate is $1.12 billion and the lowest is $1.07 billion. Perrigo reported sales of $1.29 billion during the same quarter last year, which indicates []

Related Stocks: SON , KRE , PRGO , CDK , IJR , TLT ,

This Gamma-Aminobutyric Acid (GABA) Receptor market report is based on data collected from industry professionals and market analysts across the entire chain. The end-user industry analysis depicted here assists key stakeholders in making critical decisions. The worldwide market is segmented

Related Stocks: CNNE , XLE , AMLP , UBER , PRGO , GE , GLPG , SC , BLUE ,

Balyasny Asset Management LLC cut its holdings in Perrigo Company plc (NYSE:PRGO) by 90.0% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 17,390 shares of the companys stock after selling 156,223 shares during the quarter. Balyasny Asset Management LLCs holdings []

A couple of months back we discussed that Perrigo stock, a private label over-the-counter pharmaceuticals company, may see lower levels, based on the Trefis machine learning engine, which analyzes his

Rising costs make a tough business even tougher to turn a profit.

Perrigo Company plc (PRGO) CEO Murray Kessler on Q3 2021 results - Earnings Call Transcript

Perrigo (PRGO) reports dismal third-quarter 2021 results. Stock declines.

Perrigo (PRGO) delivered earnings and revenue surprises of -30.77% and -0.84%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Perrigo Plc PRGO, -1.00% , the Dublin-based consumer self-care products maker, posted weaker-than-expected third-quarter earnings on Wednesday and issued a profit warning for the full year, after the

Perrigo's (PRGO) new products as well as products added through acquisitions are expected to have aided the company's top line in the soon-to-be-reported quarter.

Abhay Deshpande, chief investment officer at Centerstone Investors, joins 'The Exchange' with his take on markets and the economy.

A couple of months back we discussed that Perrigo stock can see higher levels after it fell 15% following a Q2 miss. PRGO stock has since risen over 17% to levels of $48 currently.

The drug company is collecting money at the same time it was able to pare back a big tax bill.